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Background
The results of multiple IL-2 clinical trials (using a range of
doses) have shown similar trends, in which IL-2 immu-
notherapy leads to an objective response in 15-20% of
patients and complete response in 5-10%. Importantly, the
majority (> 80%) of patients with a complete response
maintain long-term responses. However, why only a small
proportion of patients attain a complete response at any
dose is unknown. We hypothesized that the dose of IL-2
utilized, differentially targets CD8+ effector versus CD4+
regulatory T cells based on patient-specific characteristics,
and that an optimal IL-2 dose may be needed to achieve
therapeutic benefit.
Methods
C57BL/6 mice (10 per group) were adoptively transferred
(via retroorbital injection) with pmel CD8+ T cells (for
tracking responses; 100,000 cells) and challenged with
B16-F10 melanoma (intradermally with 120,000 cells) on
day 0. Four groups were treated on days 5-9 via intraperi-
toneal injection with IL-2 (100,000, 10,000, or 1,000 units)
or PBS only (placebo group). Tumor area was measured
every other day for 30 days. Primary outcomes included
tumor growth and T cell characterization.
Results
Tumor growth at day 14 was significantly reduced with
10,000 and 100,000 units of IL-2 (31 and 38 mm2,
respectively) compared to the placebo, (61 mm2) whereas
surprisingly, it was significantly increased with 1,000
units (96 mm2) compared to placebo (P<0.02 for all
doses versus placebo). While the number of CD8+ T
cells, CD4+ T cells, and NK cells in the tumor were simi-
lar in all groups tested, the ratio of pmel CD8+ T cells
compared to CD4+ Tregs was increased with the 10,000
and 100,000 unit doses, and decreased with the 1,000
units dose when compared to the placebo. Unexpectedly,
the 100,000 unit dose resulted in fewer pmel CD8+
T cells compared to 10,000 unit dose.
Conclusions
An optimal dose of IL-2 (here, 10,000 units) significantly
decreased tumor growth and increased overall survival
when compared to non-optimal lower or higher doses
of IL-2 in an animal melanoma model. We are now
exploring how IL-2 dose range varies among patients
and may impact clinical outcomes. Ultimately, these
findings are expected to improve therapeutic responses
and identify measurable biomarkers to optimize IL-2
dosing that can be personalized to each patient under-
going IL-2 immunotherapy.
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